Stockreport

Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

Exact Sciences Corporation  (EXAS) 
Last exact sciences corporation earnings: 2/11 04:05 pm Check Earnings Report
PDF The Cologuard Plus test demonstrated 95% sensitivity for colorectal cancer detection at 94% specificity, making it the most accurate noninvasive CRC screening test repor [Read more]